Logo image of VECT

VectivBio Holding AG (VECT) Stock Fundamental Analysis

NASDAQ:VECT - CH1109007893 - Common Stock

16.85 USD
0 (0%)
Last: 7/7/2023, 8:07:59 PM
Fundamental Rating

2

VECT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. While VECT seems to be doing ok healthwise, there are quite some concerns on its profitability. VECT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VECT had negative earnings in the past year.
VECT had a negative operating cash flow in the past year.
VECT Yearly Net Income VS EBIT VS OCF VS FCFVECT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

VECT has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VECT Yearly ROA, ROE, ROICVECT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VECT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VECT Yearly Profit, Operating, Gross MarginsVECT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for VECT has been increased compared to 1 year ago.
The debt/assets ratio for VECT is higher compared to a year ago.
VECT Yearly Shares OutstandingVECT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 20M 40M 60M
VECT Yearly Total Debt VS Total AssetsVECT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

VECT has an Altman-Z score of 17.24. This indicates that VECT is financially healthy and has little risk of bankruptcy at the moment.
VECT's Altman-Z score of 17.24 is amongst the best of the industry. VECT outperforms 93.55% of its industry peers.
VECT has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
VECT has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 17.24
ROIC/WACCN/A
WACCN/A
VECT Yearly LT Debt VS Equity VS FCFVECT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 9.14 indicates that VECT has no problem at all paying its short term obligations.
VECT has a better Current ratio (9.14) than 71.13% of its industry peers.
VECT has a Quick Ratio of 9.14. This indicates that VECT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.14, VECT is in the better half of the industry, outperforming 71.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.14
Quick Ratio 9.14
VECT Yearly Current Assets VS Current LiabilitesVECT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

VECT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.00%, which is quite impressive.
EPS 1Y (TTM)22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.85% on average over the next years. This is quite good.
The Revenue is expected to grow by 81.29% on average over the next years. This is a very strong growth
EPS Next Y8.67%
EPS Next 2Y1.86%
EPS Next 3Y1.79%
EPS Next 5Y19.85%
Revenue Next Year-96.99%
Revenue Next 2Y-36.77%
Revenue Next 3Y44.85%
Revenue Next 5Y81.29%

3.3 Evolution

VECT Yearly Revenue VS EstimatesVECT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
VECT Yearly EPS VS EstimatesVECT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VECT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VECT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VECT Price Earnings VS Forward Price EarningsVECT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VECT Per share dataVECT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.86%
EPS Next 3Y1.79%

More info and screens

0

5. Dividend

5.1 Amount

VECT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VectivBio Holding AG

NASDAQ:VECT (7/7/2023, 8:07:59 PM)

16.85

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-19 2023-04-19/amc
Earnings (Next)N/A N/A
Inst Owners0.81%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.06B
Analysts47.5
Price Target18.36 (8.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.93%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.44%
EPS NY rev (1m)0%
EPS NY rev (3m)14.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.95
P/tB 5.65
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0
BVpS3.4
TBVpS2.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.96%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.14
Quick Ratio 9.14
Altman-Z 17.24
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)27.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.83%
EPS Next Y8.67%
EPS Next 2Y1.86%
EPS Next 3Y1.79%
EPS Next 5Y19.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-96.99%
Revenue Next 2Y-36.77%
Revenue Next 3Y44.85%
Revenue Next 5Y81.29%
EBIT growth 1Y7.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-47.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.01%
OCF growth 3YN/A
OCF growth 5YN/A